Breaking: FDA approves, authorizes updated monovalent COVID-19 vaccines
Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.
Wildfire smoke raises respiratory concerns across Northeastern US
After this summer’s Canadian wildfires, should we be concerned about future air quality emergencies? This article was originally published on our sister publication’s website, Drug Topics®.
FDA amends Moderna, Pfizer EUAs to simplify use of bivalent COVID-19 vaccines
Monovalent vaccines by these manufacturers are no longer authorized for use in the United States.
Help stop the spread of influenza
Stay on the nice list with these tips to help stop the spread of winter respiratory viruses.
WHO declares monkeypox a global health emergency
The decision comes following reports of 16,000 cases across 75 countries and territories around the world.
First, only zonisamide oral suspension for treatment of partial seizures approved by FDA
The approval represents an adjunctive therapy option for pediatric patients older than age 16, as well as adults.
FDA Authorizes Pfizer-BioNTech Booster Shot for Children Ages 5 to 11
Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.
Dry eye disease, asthma relationship explored
Asthma may increase patient risk of developing dry eye disease.
New opioid disposal strategy considered by FDA
The US Food and Drug Administration (FDA) is considering dispensing mail-back envelopes with outpatient opioid analgesic prescriptions.
What's in the pipeline for mRNA technology and vaccines?
Multiple pharmaceutical companies are investigating the application of mRNA technology to develop vaccines that treat and prevent multiple conditions, from influenza to cancer and beyond.
Novavax pediatric COVID-19 vaccine trial yields positive results
The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years.
FDA extends Pfizer/BioNTech COVID-19 booster doses to teens 16-17
The US Food and Drug Administration (FDA) has extended the emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine to include a booster dose for teenagers aged 16 to 17 years.